Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508
Go back to Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 514.56 -6.56 (1.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $521.12 | 52 Week High | $134.71 | |||
| Open | $519.13 | 52 Week Low | $73.31 | |||
| Day High | $522.60 | P/E | N/A | |||
| Day Low | $514.32 | EPS | $-1.98 | |||
| Volume | 815,065 | |||||
